Clinical and immunological efficiency of different therapy regimens in patients with infectious mononucleosis caused by Epstein-Barr virus
| dc.contributor.author | Pavlikova, Ksenia | |
| dc.contributor.author | Liadova, Tetiana | |
| dc.contributor.author | Volobuieva, Olga | |
| dc.contributor.author | Gololobova, Olesya | |
| dc.contributor.author | Vinnikova, Nataliia | |
| dc.date.accessioned | 2025-04-10T09:13:27Z | |
| dc.date.issued | 2021 | |
| dc.description | The aim of the study was to evaluate the effectiveness of the drug Nuclex (ribonucleic acid) in the correction of immune disorders in patients with IM caused by EBV. The combination therapy including Nuclex and valacyclovir leads to a reduction in the duration of clinical symptoms among patients with IM compared with valacyclovir use only. Addition of Nuclex to antiviral therapy with valacyclovir improves immunogram parameters in patients with IM more effectively compared with valacyclovir use only. | |
| dc.description.abstract | The study of the role of Epstein-Barr virus (EBV) infection in the occurrence of various pathological human conditions is of great importance. This is due to the significant epidemiological role and social significance, as according to epidemiological data more than 90 % of people are already infected with EBV when they reach adulthood. The steady increase in the number of diseases caused by EBV in both adults and children, due to its specific tropism to immunocompetent cells, lifelong persistence, and latent course, necessitates a comprehensive study and development of effective treatment methods. Therefore, it is very important to conduct research to find effective treatment regimens that aim to rehabilitate the immune system, promote the regression of immune changes and complications and prevent recurrence in various forms of EBV infection. | |
| dc.identifier.citation | Pavlikova, Ksenia. Clinical and immunological efficiency of different therapy regimens in patients with infectious mononucleosis caused by Epstein-Barr virus / K. Pavlikova, T. Liadova, O. Volobueva, O. Gololobova, N. Vinnikova // EUREKA: Health Sciences. – 2021. – No. 6. – P. 3–9. – DOI: http://doi.org/10.21303/2504-5679.2021.002177 | |
| dc.identifier.doi | http://doi.org/10.21303/2504-5679.2021.002177 | |
| dc.identifier.orcid | 0000-0002-1228-4915 | |
| dc.identifier.orcid | 0000-0002-5892-2599 | |
| dc.identifier.orcid | 0000-0002-5569-1748 | |
| dc.identifier.orcid | 0000-0002-1111-2302 | |
| dc.identifier.orcid | 0000-0003-2598-4264 | |
| dc.identifier.uri | https://ekhnuir.karazin.ua/handle/123456789/21068 | |
| dc.language.iso | en | |
| dc.publisher | Tallinn : Scientific Route OÜ® | |
| dc.subject | MEDICINE | |
| dc.subject | infectious mononucleosis | |
| dc.subject | Epstein-Barr virus | |
| dc.subject | immune response | |
| dc.subject | antiviral and immunomodulatory therapy | |
| dc.title | Clinical and immunological efficiency of different therapy regimens in patients with infectious mononucleosis caused by Epstein-Barr virus | |
| dc.type | Article |
Файли
Контейнер файлів
1 - 2 з 2
Вантажиться...
- Назва:
- Договор Волобуєва Eureka,21.doc
- Розмір:
- 434 KB
- Формат:
- Microsoft Word
Вантажиться...
- Назва:
- Clinical and immunological efficiency (Scopus).pdf
- Розмір:
- 89.84 KB
- Формат:
- Adobe Portable Document Format
Ліцензійна угода
1 - 1 з 1
Вантажиться...
- Назва:
- license.txt
- Розмір:
- 8.3 KB
- Формат:
- Item-specific license agreed upon to submission
- Опис:
